OBJECTIVE: To investigate the regulation of the prostaglandin (PG) synthesis by interleukin 1 (IL-1) in human synovial cells and chondrocytes. METHODS: Both cell types stimulated by human recombinant IL-1 synthesized PGE2, PGF2 alpha and 6-keto-PGF1 alpha. RESULTS: PGE2 was the major PG synthesized. When arachidonic acid was added exogenously at the end of the stimulation, an increase in the prostaglandin synthesis was observed after 6 and 24 h suggesting that cyclooxygenase is the limiting enzyme. Using actinomycin D and cycloheximide, PG synthesis was shown to be protein synthesis dependent. Inhibition of the constitutive cyclooxygenase by aspirin before the IL-1 stimulation confirmed that the increased prostaglandin synthesis was due to a de novo synthesis of cyclooxygenase. CONCLUSION: This enzyme induction by IL-1 was found to be similar in both cell types.
OBJECTIVE: To investigate the regulation of the prostaglandin (PG) synthesis by interleukin 1 (IL-1) in human synovial cells and chondrocytes. METHODS: Both cell types stimulated by human recombinant IL-1 synthesized PGE2, PGF2 alpha and 6-keto-PGF1 alpha. RESULTS:PGE2 was the major PG synthesized. When arachidonic acid was added exogenously at the end of the stimulation, an increase in the prostaglandin synthesis was observed after 6 and 24 h suggesting that cyclooxygenase is the limiting enzyme. Using actinomycin D and cycloheximide, PG synthesis was shown to be protein synthesis dependent. Inhibition of the constitutive cyclooxygenase by aspirin before the IL-1 stimulation confirmed that the increased prostaglandin synthesis was due to a de novo synthesis of cyclooxygenase. CONCLUSION: This enzyme induction by IL-1 was found to be similar in both cell types.
Authors: P F Moore; D L Larson; I G Otterness; A Weissman; S B Kadin; F J Sweeney; J D Eskra; A Nagahisa; M Sakakibara; T J Carty Journal: Inflamm Res Date: 1996-02 Impact factor: 4.575
Authors: F Lapicque; P Vergne; J Y Jouzeau; D Loeuille; P Gillet; E Vignon; P Thomas; P Velicitat; D Türck; C Guillaume; A Gaucher; P Bertin; P Netter Journal: Clin Pharmacokinet Date: 2000-11 Impact factor: 6.447